论文部分内容阅读
[目的]用新城疫病毒(Newcastle disease virus,NDV)Ⅳ系弱毒株构建新型膜融合脂质体,并用此载体制备Hep-A22肝腹水瘤疫苗,免疫小鼠并考查疫苗的效应。[方法]用NDV制备膜融合脂质体,包封肿瘤抗原制成疫苗。体外观察NDV膜融合脂质体诱导的细胞毒性T淋巴细胞(CTL)反应活性及体内抑瘤效应。[结果]游离蛋白抗原不能诱发细胞毒T淋巴细胞反应;以膜融合脂质体为载体的疫苗可产生强烈的CTL反应(P﹤0.001),且作用强于NDV与游离蛋白混合液的肿瘤抑制作用。[结论]用NDV构建的膜融合脂质体是一种有效的肿瘤疫苗载体。
[Objective] The purpose was to construct a new type of membrane fusion liposome with Newcastle disease virus (NDV) IV strain and use the vector to prepare Hep-A22 hepatoma ascites tumor vaccine and test the effect of the vaccine. [Method] The membrane fusion liposomes were prepared by NDV and encapsulated with tumor antigen to make vaccine. The cytotoxic T lymphocyte (CTL) reactivity induced by NDV membrane fusion liposome and the anti-tumor effect in vivo were observed in vitro. [Result] The free protein antigen could not induce the cytotoxic T lymphocyte reaction. The vaccine with the membrane fusion liposome as the carrier could produce a strong CTL response (P <0.001), and the effect was stronger than that of the tumor inhibition of the NDV and free protein mixture effect. [Conclusion] The membrane-fused liposome constructed by NDV is an effective tumor vaccine vector.